Abstract
Background While it is well-known that older individuals with certain comorbidities are at highest risk for complications related to COVID-19 including hospitalization and death, we lack tools to identify communities at highest risk with fine-grained spatial and temporal resolution. Information collected at a county level obscures local risk and complex interactions between clinical comorbidities, the built environment, population factors, and other social determinants of health.
Methods We develop a robust COVID-19 Community Risk Score (C-19 Risk Score) that summarizes the complex disease co-occurrences for individual census tracts with unsupervised learning, selected on their basis for association with risk for COVID complications, such as death. We mapped the C-19 Risk Score onto neighborhoods in New York City and associated the score with C-19 related death. We further predict the C-19 Risk Score using satellite imagery data to map the built environment in C-19 Risk.
Results The C-19 Risk Score describes 85% of variation in co-occurrence of 15 diseases that are risk factors for COVID complications among 26K census tract neighborhoods (median population size of tracts: 4,091). The C-19 Risk Score is associated with a 40% greater risk for COVID-19 related death across NYC (April and September 2020) for a 1SD change in the score (Risk Ratio for 1SD change in C19 Risk Score: 1.4, p < .001). Satellite imagery coupled with social determinants of health explain nearly 90% of the variance in the C-19 Risk Score in the United States in held-out census tracts (R2 of 0.87).
Conclusions The C-19 Risk Score localizes COVID-19 risk at the census tract level and predicts COVID-19 related morbidity and mortality.
Competing Interest Statement
Chirag J Patel and Arjun K Manrai own equity in XY.Health, Inc, and are consultants to the company. Chirag M Lakhani is a consultant to the XY.Health, Inc. Andrew Deonarine is an employee of XY.Health, Inc and owns equity in the company. Genevieve Lyons is an employee of XY.Health, Inc and owns equity in the company.
Funding Statement
XY.Health, Inc provided funding for the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is not human subject research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
CDC 500 Cities and US ACS Census are publicly available. Satellite image data are available upon reasonable request. All of our code and Risk Scores are publicly available and open source (MIT license): https://github.com/xyhealth/covid_comorbidity_score
Abbreviations
- CDC
- US Center for Disease Control and Prevention
- C19
- COVID-19
- PCA
- Principal Components Analysis
- IRR
- Incidence Rate Ratio
